Long-Acting Injectables for HIV Antiretroviral Therapy
Resource updated 04/12/2024
Resource updated 04/12/2024
Resource (Conference Presentation) updated 09/14/2023
Overview of the policies, procedures, and protocols developed by an ADAP and Part C clinic to establish access to antiretrovirals, including long-acting cabotegravir/rilpivirine.
Resource (Conference Presentation) updated 09/14/2023
Resource updated 12/19/2023
Resource updated 09/19/2023
Resource updated 05/11/2023
Resource updated 04/07/2023
Among people with HIV who also inject drugs, an estimated 80 to 90 percent are coinfected with Hepatitis C (HCV.) This panel will provide updates on screening and referral activities and demonstrate how community and city partners are overcoming barriers to HCV care among PWID.
Resource (Conference Presentation) updated 09/14/2023
The first long-acting injectable antiretroviral therapy (LAI ART) formulation was FDA-approved January 2021. Drawing on the Consolidated Framework on Implementation Research, this mixed methods study assessed knowledge, attitudes, practices, and perceived barriers and facilitators related to implementation of LAI ART in NYC among HIV clinic staff and people with HIV.
Resource (Conference Presentation) updated 09/14/2023
Review of data-to-care Hennepin County, Minnesota data-to-care models to address an HIV outbreak among people who inject drugs within a housing-first, cross-sector framework.
Resource (Conference Presentation) updated 09/14/2023
Resource updated 02/02/2024
Resource updated 11/30/2023
Resource updated 02/23/2024
Module (factsheet) quick reference guide to providers and staff on frequently asked questions and answers regarding buprenorphine treatment. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.
COMPASS Dashboard notes and definitions.
Resource updated 09/14/2023
Resource updated 03/21/2024
Resource updated 09/14/2023
Resource updated 11/30/2023
Review of opioid addiction treatment, specifically buprenorphine, and its variance from methadone and naltrexone opioid addiction treatment options. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.